G6pd N126D Variant Increases the Risk of Developing VEGFR (Vascular Endothelial Growth Factor Receptor) Blocker-Induced Pulmonary Vascular Disease

G6PD (glucose-6-phosphate-dehydrogenase) is a key enzyme in the glycolytic pathway and has been implicated in the pathogenesis of cancer and pulmonary hypertension-associated vascular remodeling. Here, we investigated the role of an X-linked mutation (N126D polymorphism), which is known to increase...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of the American Heart Association 2024-10, Vol.13 (19), p.e035174
Hauptverfasser:	Signoretti, Christina, Matsumura, Shun, Fatehi, Samuel, D'Silva, Melinee, Mathew, Rajamma, Cendali, Francesca, D'Alessandro, Angelo, Alam, S M Shafiqul, Garcia, Victor, Miano, Joseph M, Gupte, Sachin A
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Disease Models, Animal Glucosephosphate Dehydrogenase - genetics Glucosephosphate Dehydrogenase - metabolism Hypertension, Pulmonary - chemically induced Hypertension, Pulmonary - genetics Hypertension, Pulmonary - metabolism Hypertension, Pulmonary - physiopathology Hypertrophy, Right Ventricular - genetics Hypertrophy, Right Ventricular - metabolism Hypertrophy, Right Ventricular - physiopathology Indoles - pharmacology Male Pulmonary Artery - drug effects Pulmonary Artery - metabolism Pulmonary Artery - pathology Pulmonary Artery - physiopathology Pyrroles Rats Rats, Sprague-Dawley Receptors, Vascular Endothelial Growth Factor - genetics Vascular Remodeling - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!